|
 |
| Activitat |
|
|
29/9/2009
|
|
 |
|
SEMINARIS PARC
Apredica: ADDME- Avoiding Drug Development Mistakes Early
Speaker: Katya Tsaioun, Aperdica's CEO > Edifici Clúster, Aula Fèlix Serratosa, 11h |
|
|
|
| The model of pharmaceutical drug development is changing. Large pharmaceutical companies are looking to academia to fill their emptying pipelines. However, there is a gap between the pharmaceutical industry expectations and the academic discovery achievements. This gap is not well funded and is not well bridged. Pharmaceutical companies are seeking de-risked, qualified, drug-like preclinical leads. Dr. Tsaioun will outline the basics of small molecule and peptide drug discovery and development including hit validation, hit expansion, hit-to-lead, lead optimization and preclinical candidate profiling stages. Methods for the academic discovery to be de-risked will be presented. New early toxicity assays that are applied at the lead optimization stage will be introduced. Then to illustrate the application of the early toxicity and other ADME properties assessment, a series of contrasting case studies will be presented, showing how some academic drug discovery programs address de-risking and out-licensing of their programs. |
|
|
|
|
|
|
 back |
|
|
|
|
|
|
|
|
